European multiple sclerosis market in dire need of increased disease awareness and treatment options, cautions Frost & Sullivan

Emergence of Innovative Treatment Options to Support Improved Compliance and
Enhanced Therapeutic Results

LONDON – 13th March 2012 – Limited awareness about the disease and its
overall occurrence and progression among end-users is hampering the European
multiple sclerosis (MS) market. This is being exacerbated by the limited
availability of accurate diagnostic tools. There is, therefore, an immediate
need for innovative and enhanced therapeutic and diagnostic tools that
support improved diagnosis and expand the range of treatment options.

New analysis from Frost & Sullivan. Analysis of
the European Multiple Sclerosis Market, finds that the market earned
revenues of approximately $3.2 billion in 2010 and estimates this to reach
approximately $5.38 billion in 2017, growing at a compound annual growth
rate (CAGR) of 7.2 per cent from 2010-2017. The segments covered include:
immunosuppressants, immunomodulators and corticosteroids.

“The rising number of people suffering from MS is resulting in higher demand
for therapeutics,” notes Frost & Sullivan Research Analyst Deepika Pramod
Chopda. “This, coupled with strong pipeline development, is pushing robust
growth in the overall market.”

MS is characterised as a chronic disease, commonly diagnosed in patients
between 20-50 years of age. It affects more than 2.5 million people across
the world, with Europe accounting for nearly 550,000 cases.

Significant research is currently underway to efficiently treat MS.
Innovative treatment therapies, including biologics and oral drugs, are
favouring market prospects.

“Refined drug delivery technologies, mode of drug delivery (oral or
injectable), and several other factors will encourage the use of MS drugs
among patients,” adds Deepika. “Novel treatment options will also promote
the concept of combination therapies, accelerating market development.”

A key challenge at present is the inaccuracy in disease diagnosis due to the
lack of sensitive diagnostic tools. Another issue is the absence of
established treatment procedures.

“Non-compliance with MS treatment procedures remains a major challenge,”
explains Deepika. “Establishing end-user confidence has become difficult due
to unsatisfactory therapeutic results.”

Cumbersome and painful procedures discourage the progress of therapy. Simple
advances, like the use of oral drugs instead of injections, will prove
beneficial to promoting compliance with therapeutic regimes.

“Awareness raising through public healthcare forums and organisations about
new developments and innovative treatment options will contribute towards
establishing greater end-user confidence,” concludes Deepika. “In the
meantime, precautionary measures like adopting healthy lifestyle practices
will help limit the incidence of the disease.”

Analysis of the European Multiple Sclerosis is part of the Pharmaceuticals &
Biotechnology Growth Partnership Service programme, which also includes
research in the following markets: European Biosimilars Market, Global
Generics Market and European Autoimmune Diseases Therapeutics Market. All
research included in subscriptions provide detailed market opportunities and
industry trends that have been evaluated following extensive interviews with
market participants.

Recent Issues